nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

27.07.2018 | Original Article

Prognostic significance of normalized FDG-PET parameters in patients with multiple myeloma undergoing induction chemotherapy and autologous hematopoietic stem cell transplantation: a retrospective single-center evaluation

verfasst von: Daria Ripani, Carmelo Caldarella, Tommaso Za, Daniele Antonio Pizzuto, Elena Rossi, Valerio De Stefano, Alessandro Giordano

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The purpose of this study was to determine retrospectively, through a single-center evaluation, whether FDG PET-CT normalized semi-quantitative parameters may predict response to induction chemotherapy (iChT) and hematopoietic stem cell transplantation (HSCT), as well as disease progression and progression-free survival in multiple myeloma (MM) patients, thus becoming a tool of personalized medicine.

Methods

Patients undergoing iChT and HSCT with baseline and post-treatment FDG PET-CTs from January 2008 to July 2015 were included. The following baseline and post-treatment parameters were obtained: SUVmax, SUVmean, SUVpeak, MTVsum, TLGsum, rPET (lesion SUVmax/liver SUVmax) and qPET (lesion SUVpeak/liver SUVmean). Baseline-to-post-treatment changes (Δ) were also calculated. Metabolic and clinical laboratory progression or response at follow-up were noted; time-to-metabolic-progression (TMP) was defined as the interval from post-treatment scan to eventual progression at follow-up FDG PET-CTs. Possible association between each functional parameter and metabolic/clinical-laboratory progression or response was determined. Kaplan-Meier curves allowed to depict the TMP trend according to FDG PET-CT parameters.

Results

Twenty-eight patients were included. Significantly higher ΔrPET and ΔqPET values were observed in ten patients with “metabolic response”, with respect to 18 patients having “metabolic progression” (median 0.62 [IQR 0.32 – 1.34] vs median 0.00 [IQR -0.25 – 0.49] for ΔrPET; P = 0.045; median 0.51 [IQR 0.32 – 1.13] vs median 0.00 [IQR -0.31 – 0.67] for ΔqPET; P = 0.035). Neither normalized nor non normalized parameters differed significantly between the 20 patients with “clinical-laboratory response” and the eight patients with “clinical-laboratory progression”. ΔrPET value lower than 0.38 and ΔqPET value lower than 0.27 predicted a significantly shorter TMP (P = 0.003 and P = 0.005, respectively).

Conclusions

Normalized semi-quantitative parameters are effective in predicting persistent response to treatment and shorter TMP in patients with MM undergoing iChT and HSCT.

Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, et al. Multiple myeloma: ESMO clinical practice guidelines. Ann Oncol. 2017;28(suppl.4):iv52–61.CrossRef

Kehrer M, Koob S, Strauss A, Wirtz DC, Schmolders J. Multiple myeloma—current status in diagnostic testing and therapy. Z Orthop Unfall. 2017;155:575–86. https://doi.org/10.1055/s-0043-110224.CrossRefPubMed

Qian J, Jin J, Luo H, Jin C, Wang L, Qian W, et al. Analysis of clinical characteristics and prognostic factors of multiple myeloma: a retrospective single-center study of 787 cases. Hematology. 2017;22:472–6. https://doi.org/10.1080/10245332.2017.1309493.CrossRefPubMed

Castillo JJ, Jurczyszyn A, Brozova L, Crusoe E, Czepiel J, Davila J, et al. IgM myeloma: a multicenter retrospective study of 134 patients. Am J Hematol. 2017;92:746–51. https://doi.org/10.1002/ajh.24753.CrossRefPubMed

Howell D, Smith A, Appleton S, Bagguley T, Macleod U, Cook G, et al. Multiple myeloma: routes to diagnosis, clinical characteristics and survival—findings from a UK population-based study. Br J Haematol. 2017;177:67–71. https://doi.org/10.1111/bjh.14513.CrossRefPubMedPubMedCentral

Kumar S, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Geyer S, et al. High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. Bone Marrow Transplant. 2004;34:161–7.CrossRef

Mohty M, Harousseau JL. Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answers. Haematologica. 2014;99:408–16.CrossRef

Morris C, Iacobelli S, Brand R, Bjorkstrand B, Drake M, Niederwieser D, et al. Chronic Leukaemia Working Party Myeloma Subcommittee, European Group for Blood and Marrow Transplantation. Benefit and timing of second transplantations in multiple myeloma: clinical findings and methodological limitations in a European Group for Blood and Marrow Transplantation registry study. J Clin Oncol. 2004;22:1674–81.CrossRef

Gay F, Engelhardt M, Terpos E, Wäsch R, Giaccone L, Auner HW, et al. From transplant to novel cellular therapies in multiple myeloma: EMN guidelines and future perspectives. Haematologica. 2017. https://doi.org/10.3324/haematol.2017.174573.CrossRef

10.

Mesguich C, Fardanesh R, Tanenbaum L, Chari A, Jagannath S, Kostakoglu L. State of the art imaging of multiple myeloma: comparative review of FDG PET/CT imaging in various clinical settings. Eur J Radiol. 2014;83:2203–23. https://doi.org/10.1016/j.ejrad.2014.09.012.CrossRefPubMed

11.

Ho CL, Chen S, Leung YL, Cheng T, Wong KN, Cheung SK, et al. 11C-acetate PET/CT for metabolic characterization of multiple myeloma: a comparative study with 18F-FDG PET/CT. J Nucl Med. 2014;55:749–52. https://doi.org/10.2967/jnumed.113.131169.CrossRefPubMed

12.

Dammacco F, Rubini G, Ferrari C, Vacca A, Racanelli V. ¹⁸F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders. Clin Exp Med. 2015;15:1–18. https://doi.org/10.1007/s10238-014-0308-3.CrossRefPubMed

13.

Chantry A, Kazmi M, Barrington S, Goh V, Mulholland N, Streetly M, et al. Guidelines for the use of imaging in the management of patients with myeloma. Br J Haematol. 2017;178:380–93. https://doi.org/10.1111/bjh.14827.CrossRefPubMed

14.

Yu Q, Shi JM, Tao Y. Clinical significance and detection techniques of minimal residual disease in multiple myeloma-review. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017;25:961–4. https://doi.org/10.7534/j.issn.1009-2137.2017.03.059.CrossRefPubMed

15.

Nanni C, Zamagni E. Therapy assessment in multiple myeloma with PET. Eur J Nucl Med Mol Imaging. 2017;44(Suppl 1):111–7. https://doi.org/10.1007/s00259-017-3730-4.CrossRefPubMed

16.

Fonti R, Larobina M, Del Vecchio S, De Luca S, Fabbricini R, Catalano L, et al. Metabolic tumor volume assessed by 18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma. J Nucl Med. 2012;53:1829–35. https://doi.org/10.2967/jnumed.112.106500.CrossRefPubMed

17.

McDonald JE, Kessler MM, Gardner MW, Buros AF, Ntambi JA, Waheed S, et al. Assessment of total lesion glycolysis by 18F-FDG PET/CT significantly improves prognostic value of GEP and ISS in myeloma. Clin Cancer Res. 2017;23:1981–7.CrossRef

18.

Annunziata S, Cuccaro A, Calcagni ML, Hohaus S, Giordano A, Rufini V. Interim FDG-PET/CT in Hodgkin lymphoma: the prognostic role of the ratio between target lesion and liver SUVmax (rPET). Ann Nucl Med. 2016;30:588–92. https://doi.org/10.1007/s12149-016-1092-9.CrossRefPubMed

19.

Hasenclever D, Kurch L, Mauz-Korloz C, Elsner A, Georgi T, Wallace H, et al. qPET—a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:1301–8. https://doi.org/10.1007/s00259-014-2715-9.CrossRefPubMed

20.

Sachpekidis C, Mai EK, Goldschmidt H, Hillengass J, Hose D, Pan L, et al. (18)F-FDG dynamic PET/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate. Clin Nucl Med. 2015;40:e300–7. https://doi.org/10.1097/RLU.0000000000000773.CrossRefPubMed

21.

Aide N, Lasnon C, Veit-Haibach P, Sera T, Sattler B, Boellaard R. EANM/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies. Eur J Nucl Med Mol Imaging. 2017;44(Suppl 1):17–31. https://doi.org/10.1007/s00259-017-3740-2.CrossRefPubMedPubMedCentral

22.

Sachpekidis C, Hillengass J, Goldschmidt H, Wagner B, Haberkorn U, Kopka K, et al. Treatment response evaluation with ₁₈F-FDG PET/CT and ₁₈F-NaF PET/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation. Eur J Nucl Med Mol Imaging. 2017;44:50–62.CrossRef

23.

Albano D, Bosio G, Treglia G, Giubbini R, Bertagna F. 18F-FDG PET/CT in solitary plasmacytoma: metabolic behavior and progression to multiple myeloma. Eur J Nucl Med Mol Imaging. 2018;45:77–84. https://doi.org/10.1007/s00259-017-3810-5.CrossRefPubMed

24.

Zamagni E, Patriarca F, Nanni C, Zannetti B, Englaro E, Pezzi A, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118:5989–95. https://doi.org/10.1182/blood-2011-06-361386.CrossRefPubMed

25.

Usmani SZ, Mitchell A, Waheed S, Crowley J, Hoering A, Petty N, et al. Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. Blood. 2013;121:1819–23. https://doi.org/10.1182/blood-2012-08-451690.CrossRefPubMedPubMedCentral

26.

Patriarca F, Carobolante F, Zamagni E, Montefusco V, Bruno B, Englaro E, et al. The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2015;21:1068–73. https://doi.org/10.1016/j.bbmt.2015.03.001.CrossRefPubMed

27.

Haznedar R, Akı SZ, Akdemir OU, Ozkurt ZN, Ceneli O, Yağcı M, et al. Value of 18F-fluorodeoxyglucose uptake in positron emission tomography/computed tomography in predicting survival in multiple myeloma. Eur J Nucl Med Mol Imaging. 2011;38:1046–53. https://doi.org/10.1007/s00259-011-1738-8.CrossRefPubMed

28.

Dankerl A, Liebisch P, Glatting G, Friesen C, Blumstein NM, Kocot D, et al. Multiple myeloma: molecular imaging with 11C-methionine PET/CT--initial experience. Radiology. 2007;242:498–508.CrossRef

29.

Nanni C, Zamagni E, Celli M, Caroli P, Ambrosini V, Tacchetti P, et al. The value of 18F-FDG PET/CT after autologous stem cell transplantation (ASCT) in patients affected by multiple myeloma (MM): experience with 77 patients. Clin Nucl Med. 2013;38:e74–9. https://doi.org/10.1097/RLU.0b013e318266cee2.CrossRefPubMed

30.

Isoda A, Higuchi T, Nakano S, Arisaka Y, Kaira K, Kamio T, et al. ¹⁸F-FAMT in patients with multiple myeloma: clinical utility compared to ¹⁸F-FDG. Ann Nucl Med. 2012;26:811–6. https://doi.org/10.1007/s12149-012-0645-9.CrossRefPubMed

Titel: Prognostic significance of normalized FDG-PET parameters in patients with multiple myeloma undergoing induction chemotherapy and autologous hematopoietic stem cell transplantation: a retrospective single-center evaluation
verfasst von: Daria Ripani
Carmelo Caldarella
Tommaso Za
Daniele Antonio Pizzuto
Elena Rossi
Valerio De Stefano
Alessandro Giordano
Publikationsdatum: 27.07.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 1/2019
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-018-4108-y

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy

C.R. Goldfarb, M. Chamarthy, F. Ongseng, S.R. Parmett, D.L. Bushnell, R. Mirtcheva-Trocheva, U. Sen, L.S. Zuckier. Nuclear Medicine Board Review: Questions and answers for self-assessment, 4th Edition

FDG PET/CT imaging in detecting and guiding management of invasive fungal infections: a retrospective comparison to conventional CT imaging

Contribution of PET imaging to mortality risk stratification in candidates to lead extraction for pacemaker or defibrillator infection: a prospective single center study

Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in Burkitt lymphoma

68Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng/ml. Efficacy and impact on treatment strategy